London, United Kingdom (Press Release) – GlaxoSmithKline plc (LSE/NYSE: GSK) to­day an­nounced that it has re­ceived Break­through Therapy Desig­na­tion from the U.S. Food and Drug Admin­istra­tion (FDA) for GSK2857916 mono­­therapy in patients with mul­ti­ple myeloma who have failed at least three prior lines of ther­apy, in­­clud­ing an anti-CD38 anti­body and are re­frac­tory to a pro­te­a­some in­hib­i­tor and an immuno­modulatory agent. In Octo­ber, the Euro­pean Medicines Agency (EMA) granted PRIME desig­na­tion to GSK2857916 for the treat­ment of re­lapsed and re­frac­tory mul­ti­ple myeloma patients whose prior ther­apy in­cluded a pro­te­a­some in­hib­i­tor, an immuno­modulatory agent …

• Collaboration Includes BCMA CAR Constructs with Fully-Human Binding Domains
• Potential to Accelerate Juno’s Multiple Myeloma Program

Seattle, WA, New York, NY, and Emeryville, CA (Press Release) – Juno Thera­peutics, Inc. (Nasdaq: JUNO), a bio­pharma­ceu­tical com­pany focused on re-engaging the body's immune sys­tem to revolutionize the treat­ment of cancer, announced today that it has entered into an exclusive license agree­ment with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Thera­peutics, Inc. for a novel, fully-human binding domain targeting B-cell maturation an­ti­gen (BCMA), along with binding domains against two addi­tional undisclosed multiple myeloma targets to be used for the poten­tial devel­op­ment and com­mer­cial­iza­tion …